e-Drug3D

2133

ATRASENTAN

INN
ATRASENTAN

cas 173937-91-2

CLASS

CARDIOVASCULAR
ENDOTHELIN RECEPTOR ANTAGONIST (KI = 0.034 NANOMOLAR)
REDUCE PROTEINURIA IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) AT RISK OF RAPID DISEASE PROGRESSION

ROUTE (list)

ORAL

ATC code

PK parameters

Tmax 0.5 HOUR
VD 1180 LITER
Cl 19 LITER / HOUR
PPB 99 PERCENT
t1/2 32.5 HOUR

Solubility

SLIGHTLY SOLUBLE IN WATER

Target

TARGET ENDOTHELIN RECEPTOR TYPE A ETA

DrugCentral

Download SDF file

3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-, (2R,3R,4S)-

Formula:
C29H38N2O6

Calculated chemical properties:

MW 509.61
NB_atoms 37
XLogP 3.36
PSA 92.222
NB_HD 0
NB_HA 8
fsp3 0.52
Lipinski(0=no;1=yes) 0

FDA
NDA 219208 (label) INN (ATRASENTAN HYDROCHLORIDE) VANRAFIA (NOVARTIS) APPROVAL= AP YEAR= 2025 NEWMOLECULARENTITY